Alkermes plc is a fully integrated, global biopharmaceutical company committed to developing innovative medicines for the treatment of central nervous system (CNS) diseases and cancer. The company has a diverse portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, alongside a pipeline of R&D programs in neuroscience and oncology. Alkermes leverages its scientific expertise and proprietary technologies to address unmet medical needs and improve patient outcomes.
The Dublin headquarters serves as the central corporate and administrative hub, overseeing global strategy, finance, legal affairs, and international commercial operations.
Located in a modern office building in a key business district, designed to support corporate functions and global management.
The headquarters fosters a collaborative and performance-driven work environment, reflecting Alkermes' commitment to innovation and addressing serious medical conditions. It connects global teams focused on patient care.
Its Irish headquarters underscores Alkermes' global operational structure and provides strategic access to European markets and regulatory bodies. Ireland's established pharmaceutical sector also offers a supportive business environment.
Alkermes operates with a global footprint, anchored by its corporate headquarters in Dublin, Ireland. Key operational, research, and manufacturing functions are distributed across strategic locations in the United States (Waltham, Massachusetts, and Wilmington, Ohio) and Ireland (Athlone). These facilities collectively support the company's end-to-end capabilities, from drug discovery and development to manufacturing and commercialization of medicines for patients worldwide, primarily in the fields of neuroscience and oncology.
Connaught House, 1 Burlington Road
Dublin 4
Dublin
Ireland
Address: 852 Winter Street, Waltham, MA 02451, USA
Drives innovation through cutting-edge R&D, supports clinical development programs, and manages U.S. commercialization efforts for Alkermes' portfolio.
Address: 301 E. Mulberry Street, Wilmington, OH 45177, USA
Ensures the reliable supply and high-quality production of Alkermes' medicines for the U.S. and global markets, playing a critical role in the company's supply chain.
Address: Monksland Industrial Estate, Athlone, Co. Westmeath, Ireland
Supports global product development and manufacturing, particularly for advanced drug delivery systems. It leverages Ireland's strong pharmaceutical talent pool and infrastructure.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Alkermes' leadership includes:
Alkermes has been backed by several prominent investors over the years, including:
Alkermes executed a significant leadership transition in late 2023 and early 2024, appointing new executives to critical roles including Chief Commercial Officer, Chief Legal Officer, SVP Human Resources, and SVP Operations & Quality, primarily effective January 2024. This was complemented by the earlier appointment of a new Chief Medical Officer in May 2023. These changes also included the departures of the former Chief Commercial Officer, Chief Legal Officer, and Chief Operating Officer at the end of 2023.
Discover the tools Alkermes uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Alkermes plc typically utilizes a standard corporate email format. The most common structure is 'first.last@alkermes.com'. Variations such as 'first_initiallast@alkermes.com' might also be in use for some employees or specific circumstances.
first.last@alkermes.com
Format
jane.doe@alkermes.com
Example
85%
Success rate
Business Wire • April 24, 2024
Alkermes plc announced its financial results for the first quarter of 2024, reporting total revenues of $379.8 million. The company also raised its full-year 2024 financial expectations, driven by strong performance of its proprietary products....more
Alkermes Official Website • May 6, 2024
Alkermes plc announced it will present 12 posters featuring new clinical and real-world data for LYBALVI® (olanzapine and samidorphan) and its ARISTADA® (aripiprazole lauroxil) product family at the American Psychiatric Association (APA) Annual Meeting, held May 4-8, 2024, in New York City....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Alkermes, are just a search away.